GM-CSF Antibody, anti-human, REAfinity™
Synonyms: CSF2
RECOMBINANT EXTENDED VALIDATION
Bioz Star94/100 Bioz rating
9 Citations
Clone:
REA1215 | BVD2-21C11
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for GM-CSF Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
Vio B515
Description:
Human peripheral blood mononuclear cells (PBMCs) were either left unstimulated (left images) or stimulated with 50 ng/mL PMA and 1 µg/mL ionomycin for four hours. Cells were then fixed, permeabilized, and stained with Anti-GM-CSF antibodies as well as with CD4 antibodies. Flow cytometry was performed using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.
Intracellular flow cytometry applications
APC
APC-Vio 770
PE
PE-Vio 615
PE-Vio 770
Vio B515
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-123-427, 130-123-420
Description:
Human peripheral blood mononuclear cells (PBMCs) were either left unstimulated (left images) or stimulated with 50 ng/mL PMA and 1 µg/mL ionomycin for four hours. Cells were then fixed, permeabilized, and stained with Anti-GM-CSF antibodies as well as with CD4 antibodies. Flow cytometry was performed using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application imageView details view details

Application imageView details view details
Extended validation for GM-CSF Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA1215
BVD2-21C11
high
DAVKAT
low

Cells were incubated with an excess of purified unconjugated GM-CSF (REA1215) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for GM-CSF. Human peripheral blood mononuclear cells (PBMCs) were stimulated with PMA & Ionomycin and were stained with GM-CSF antibodies and with a suitable counterstaining. Cells were then fixed and permeabilized using the Inside Stain Kit followed by a staining with (specificity from PIM) antibodies. As a control, GM-CSF antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and Viobility 405/520 Fixable Dye fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Specifications for GM-CSF Antibody, anti-human, REAfinity™
Overview

Clone REA1215 recognizes the human granulocyte macrophage colony-stimulating factor (GM-CSF), which is a hematopoietic growth factor that is essential for proliferation and development of granulocyte and monocyte/macrophage progenitors. It also functions as a growth factor for erythroid and megakaryocytic precursor cells in conjunction with erythropoietin. GM-CSF is secreted by various cell types including T cells, macrophages, endothelial cells, and fibroblasts in response to inflammatory stimuli and cytokines. In addition, GM-CSF strongly chemoattracts neutrophils and eosinophils and enhances the effector functions of neutrophils and macrophages.

Additional information: Clone REA1215 displays negligible binding to Fc receptors.

Alternative names

CSF2

Detailed product information

Technical specifications

Clone
REA1215
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human, non-human primate
Cross-reactivity
rhesus monkey (Macaca mulatta), cynomolgus monkey (Macaca fascicularis)
Antigen
GM-CSF
Molecular mass of antigen [kDa]
14
Distribution of antigen
T cells, endothelial cells, fibroblasts, macrophages, other
Entrez Gene ID
RRID
AB_2811522, AB_2811517, AB_2811520, AB_2811519, AB_2811515, AB_2811516, AB_2922005, AB_2811521, AB_2811518, AB_2922022

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for GM-CSF Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?